Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time (Q37155376)

18 August 2017

Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time (English)

1 reference

18 August 2017

8

Philip W Kantoff

1 reference

18 August 2017

7

James L Gulley

1 reference

18 August 2017

11

Meredith M Regan

1 reference

18 August 2017

4

Anthony D'Amico

1 reference

18 August 2017

Philip M Arlen

1

1 reference

18 August 2017

Fernando Bianco

2

1 reference

18 August 2017

William L Dahut

3

1 reference

18 August 2017

William D Figg

5

1 reference

18 August 2017

Stephen J Freedland

6

1 reference

18 August 2017

Michael W Kattan

9

1 reference

18 August 2017

Andrew Lee

10

1 reference

18 August 2017

Oliver Sartor

12

1 reference

18 August 2017

Prostate Specific Antigen Working Group

13

1 reference

18 August 2017

language of work or name

English

0 references

publication date

18 April 2008

1 reference

18 August 2017

1 reference

18 August 2017

179

1 reference

18 August 2017

6

1 reference

18 August 2017

2181-5; discussion 2185-6

1 reference

Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667701

6 September 2017

Cancer statistics, 2006

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667701

A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667701

Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667701

Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667701

Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667701

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667701

High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667701

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667701

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667701

A prognostic score for hormone-refractory prostate cancer: analysis of two cancer and leukemia group B studies.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667701

Observations on the doubling time of prostate cancer.The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667701

Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy

3 September 2018

1 reference

12 December 2020

PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time

1 reference

12 December 2020

Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer

1 reference

12 December 2020

Temporal (circadian) and functional relationship between prostate-specific antigen and testosterone in healthy men

1 reference

12 December 2020

Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality

1 reference

12 December 2020

Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations

1 reference

12 December 2020

Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure

1 reference

12 December 2020

10.1016/J.JURO.2008.01.099

Identifiers

DOI

1 reference

18 August 2017

1 reference

18 August 2017

PubMed publication ID

18423743

1 reference